WO2023057931 - MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF
National phase entry:
Publication Number
WO/2023/057931
Publication Date
13.04.2023
International Application No.
PCT/IB2022/059520
International Filing Date
05.10.2022
Title **
[English]
MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF
[French]
CELLULES IMMUNITAIRES MODIFIÉES ET LEURS MÉTHODES D'UTILISATION
Applicants **
UNIVERSITY HEALTH NETWORK
101 College Street, Unit 150
Toronto, Ontario M5G 1L7, CA
Inventors
DINIZ DE CARVALHO, Daniel
c/o University Health Network
101 College Street, Unit 150
Toronto, Ontario M5G 1L7, CA
LOO YAU, Helen
c/o University Health Network
101 College Street, Unit 150
Toronto, Ontario M5G 1L7, CA
ETTAYEBI, Ilias
c/o University Health Network
101 College Street, Unit 150
Toronto, Ontario M5G 1L7, CA
Priority Data
63/253,001
06.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2366 | |
| EPO | Filing, Examination | 20189 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 9110 |
Total: 32834 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure is directed to methods of treating a subject in need thereof, comprising administering to the subject a population of modified immune cells, which comprises one or more modified immune cells having decreased expression of one or more components of the SAGA (Spt–Ada–Gcn5–acetyltransferase) complex, relative to an unmodified immune cell. In some aspects, the immune cell comprises a chimeric antigen receptor or a T cell receptor. In some aspects, the immune cell is a T cell, an NK cell, or a tumor infiltrating lymphocyte (TIL).[French]
La présente invention concerne des méthodes de traitement d'un sujet en ayant besoin, qui consistent à administrer au sujet d'une population de cellules immunitaires modifiées, qui comprend une ou plusieurs cellules immunitaires modifiées ayant une expression réduite d'un ou plusieurs composants du complexe SAGA (Spt-Ada-Gcn5-acétyltransférase) par rapport à une cellule immunitaire non modifiée. Dans certains aspects, la cellule immunitaire comprend un récepteur antigénique chimérique ou un récepteur des cellules T. Dans certains aspects, la cellule immunitaire est une cellule T, une cellule NK, ou un lymphocyte infiltrant les tumeurs (TIL).